RICHTER, Suzanne et al. Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib. Canadian Urological Association Journal, [S. l.], v. 8, n. 11-12, p. 398–402, 2014. DOI: 10.5489/cuaj.2426. Disponível em: https://cuaj.ca/index.php/journal/article/view/2426. Acesso em: 1 may. 2026.